Spector-Bagdady Kayte, Kent Madison, Krenz Chris D, Brummel Collin, Swiecicki Paul L, Brenner J Chad, Shuman Andrew G
Center for Bioethics and Social Sciences in Medicine, University of Michigan Medical School, Ann Arbor, MI, United States.
Department of Obstetrics and Gynecology, University of Michigan Medical School, Ann Arbor, MI, United States.
JMIR Cancer. 2022 May 3;8(2):e35033. doi: 10.2196/35033.
The genomic frontier continues to revolutionize the practice of oncology. Advances in cancer biology from tumorigenesis to treatment resistance are driven by the molecular underpinnings of malignancy. The framing of precision oncology as both a clinical and research tool is constantly evolving and directly influences conversations between oncologists and their patients. Prior research has shown that patient-participants often have unmet or unrealistic expectations regarding the clinical utility of oncology research and genomic sequencing. This indicates the need for more in-depth investigation of how and why patients choose to participate in such research.
This study presents a qualitative ethical analysis to better understand patient and provider perspectives on enrollment in precision oncology research.
Paired semistructured interviews were conducted with patient-participants enrolled in a prospective head and neck precision oncology research platform, along with their oncology providers, at a National Cancer Institute-designated academic cancer center.
There were three major themes that emerged from the analysis. (1) There are distinct and unique challenges with informed consent to precision medicine, chiefly involving the ability of both patient-participants and providers to effectively understand the science underlying the research. (2) The unique benefits of precision medicine enrollment are of paramount importance to patients considering enrollment. (3) Patient-participants have little concern for the risks of research enrollment, particularly in the context of a low-burden protocol.
Patient-participants and their providers offer complementary and nuanced perspectives on their motivation to engage in precision oncology research. This reflects both the inherent promise and enthusiasm within the field, as well as the limitations and challenges of ensuring that both patient-participants and clinicians understand the complexities of the science involved.
基因组前沿领域持续革新肿瘤学实践。从肿瘤发生到治疗耐药性,癌症生物学的进展由恶性肿瘤的分子基础驱动。精准肿瘤学作为一种临床和研究工具,其框架不断演变,直接影响肿瘤学家与患者之间的交流。先前的研究表明,患者参与者对肿瘤学研究和基因组测序的临床效用往往有未满足的期望或不切实际的预期。这表明需要更深入地研究患者选择参与此类研究的方式和原因。
本研究进行了定性伦理分析,以更好地理解患者和提供者对参与精准肿瘤学研究的看法。
在一家国立癌症研究所指定的学术癌症中心,对参与前瞻性头颈精准肿瘤学研究平台的患者参与者及其肿瘤学提供者进行了配对半结构化访谈。
分析得出三个主要主题。(1)精准医学知情同意存在独特且明显的挑战,主要涉及患者参与者和提供者有效理解研究背后科学的能力。(2)精准医学入组的独特益处对考虑入组的患者至关重要。(3)患者参与者对研究入组的风险几乎不担心,特别是在方案负担较低的情况下。
患者参与者及其提供者对参与精准肿瘤学研究的动机提供了互补且细致入微的观点。这既反映了该领域内在的前景和热情,也反映了确保患者参与者和临床医生理解所涉科学复杂性的局限性和挑战。